Most broken bones after 50 happen to women without osteoporosis

TODAY'S TOPIC

Bone Health and Osteoporosis

CLAIM 01

"Most broken bones in women over 50 happen to women who do not have osteoporosis."

VERDICT: TRUTH

This sounds backward. Osteoporosis is supposed to be the condition that causes fractures.

But a T-score of -2.5 or lower is a diagnostic threshold, not a cliff edge. Far more women over 50 fall into the osteopenia range, the zone between normal and osteoporosis, than meet the criteria for osteoporosis itself.

Because that middle group is so much larger, it produces more total fractures even though each individual's risk is lower. Well-established research, including a large analysis of over 200,000 postmenopausal women published in JAMA, has confirmed this pattern.

A scan result of "not quite osteoporosis" is not a clean bill of health. Fall risk, age, prior fractures, and family history shape your fracture odds as much as the number on the report.

THE RESEARCH

NIH NIAMS: Osteoporosis Overview

Bone Health & Osteoporosis Foundation

Siris ES, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA, 2001.

CLAIM 02

"Osteoporosis drugs can cause the exact type of fracture they are supposed to prevent."

VERDICT: MYTH

This fear is not invented. Bisphosphonates, the most widely prescribed osteoporosis drugs, slow bone breakdown so effectively that over many years, bone can lose some ability to repair microscopic stress damage.

The result is a rare event called an atypical femoral fracture: a clean break in the thighbone shaft, sometimes with minimal force. The FDA added a warning about this risk in 2010.

Here is what the fear leaves out. These fractures occur in roughly 1 to 5 per 10,000 patient-years of use, while standard hip and spine fractures prevented by the same drugs number in the hundreds per 10,000.

For most women at meaningful fracture risk, the math overwhelmingly favors treatment. The practical step is a conversation about whether a drug holiday makes sense after three to five years on a bisphosphonate.

THE RESEARCH

FDA Drug Safety Communication: Bisphosphonates and Atypical Fractures (2010)

Shane E, et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2014.

CLAIM 03

"Once bone is lost after menopause, no medication can build it back."

VERDICT: MYTH

For most of modern medicine, this was basically true. Every available drug could slow further loss but could not replace what was already gone.

That changed with a class of drugs called anabolic bone agents. Teriparatide, approved in 2002, and romosozumab, approved in 2019, stimulate the cells that form new bone rather than just blocking the cells that remove it.

In clinical trials, romosozumab increased spine bone density by about 13% and hip density by about 7% in twelve months. For a woman with severe osteoporosis, that kind of gain can shift her out of the highest-risk zone.

These drugs are reserved for women at high fracture risk and used for a limited window of one to two years before switching to a maintenance medication. But the claim that lost bone is gone forever is no longer accurate.

RESOURCE: GUIDE

Osteoporosis: Diagnosis, Treatment, and Steps to Take

NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases

THE RESEARCH

Cosman F, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2016.

Neer RM, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2001.

THE BOTTOM LINE

Your bone density score is one piece of a larger conversation. The tools for protecting and even rebuilding bone are better than most women have been told.

Which verdict surprised you most?

One tap. It decides what we dig into next.